We are live on ! Find out more
NWBO

Northwest Biotherapeutics
NWBO

Delisted

NWBO was delisted on the 16th of December, 2016.

58 hedge funds and large institutions have $52.5M invested in Northwest Biotherapeutics in 2014 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 19 increasing their positions, 12 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

467% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 3

209% more capital inflows, than outflows

Capital inflows: $11M | Capital outflows: $3.55M

58% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 12

51% more call options, than puts

Call options by funds: $4.19M | Put options by funds: $2.78M

32% more funds holding

Funds holding: 44 → 58 (+14)

13.49% more ownership

Funds ownership: 0% → 13.49% (+13%)

Holders
58
Holders Change
+14
Holders Change %
+31.82%
% of All Funds
1.67%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
17
Increased
19
Reduced
12
Closed
3
Calls
$4.19​M
Puts
$2.78​M
Net Calls
+$1.41​M
Net Calls Change
+$2.25​M

NWBO Hedge Fund Activity: Q1 2014 in Review

58 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics (NWBO) for Q1 2014, worth a combined $52.5M — up 124% from $23.5M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new NWBO positions and 3 closed out — a net gain of 14 holders — while 19 added to existing stakes and 12 trimmed.

The largest buyer was Franklin Resources, adding an estimated $2.03M. The largest seller was Whitebox Advisors, exiting entirely with an estimated $2.07M sold.

  • 58 institutional investors held Northwest Biotherapeutics (NWBO) as of Q1 2014, up from 44 in Q4 2013.
  • Funds reported $52.5M of Northwest Biotherapeutics stock for Q1 2014, up 124% quarter-over-quarter.
  • 17 funds opened new Northwest Biotherapeutics positions in Q1 2014 and 3 closed out, a net change of +14 holders.
  • The largest Northwest Biotherapeutics buyer in Q1 2014 was Franklin Resources, an estimated $2.03M added.
  • The largest Northwest Biotherapeutics seller in Q1 2014 was Whitebox Advisors, an estimated $2.07M sold.

Based on aggregated 13F filings for Q1 2014.